Zentrum für Neuroonkologie Universitätsklinikum Tübingen
Welcome,         Profile    Billing    Logout  
 1 Trial 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tabatabai, Ghazaleh
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
LEGATO, NCT05904119: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Recruiting
3
411
Europe, RoW
Lomustine, Reirradiation
European Organisation for Research and Treatment of Cancer - EORTC, Swiss Group for Clinical Cancer Research
First Progression of Glioblastoma
09/27
02/28
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
PersoMed-I, NCT04402073 / 2020-003063-26: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Active, not recruiting
2
20
Europe, RoW
Sonidegib, Cisplatin, Lomustine, Vincristine, radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC, EORTC-BTG, Sunpharmaceuticals
Medulloblastoma
04/25
04/25
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25
GLIO-XS15, NCT04842513: Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma

Completed
1
15
Europe
Multipeptide plus XS15
University Hospital Tuebingen
Glioblastoma Multiforme of Brain
07/24
07/24
INTERCEPT-H3, NCT04808245: A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Recruiting
1
15
Europe
Tecentriq 1200 MG in 20 ML Injection, Atezolizumab, H3K27M peptide vaccine, Imiquimod (5%), Aldara
German Cancer Research Center, Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid
Newly Diagnosed H3-mutated Glioma
03/25
03/25
NCT05112549: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

Recruiting
1
46
Europe
Nivolumab [Opdivo]
University Hospital Tuebingen
Leptomeningeal Disease
09/25
09/26
NCT06146010: Non Interventional German Leptomeningeal Disease Register

Recruiting
N/A
50
Europe
No intervention
University Hospital Tuebingen
Meningeal Neoplasms, Leptomeningeal Disease
01/29
12/29
MTB@ZPM, NCT03503149: Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Recruiting
N/A
1000
Europe
no intervention
University Hospital Tuebingen
Advanced Cancer
03/28
03/28

Download Options